# Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

> **NCT00286169** · PHASE3 · TERMINATED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** Amrubicin Hydrochloride

## Key facts

- **NCT ID:** NCT00286169
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00286169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00286169, "Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00286169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*